RAGE Signaling in Melanoma Tumors.
Olamide Tosin OlaobaSultan KadasahStefan W VetterEstelle LeclercPublished in: International journal of molecular sciences (2020)
Despite recent progresses in its treatment, malignant cutaneous melanoma remains a cancer with very poor prognosis. Emerging evidences suggest that the receptor for advance glycation end products (RAGE) plays a key role in melanoma progression through its activation in both cancer and stromal cells. In tumors, RAGE activation is fueled by numerous ligands, S100B and HMGB1 being the most notable, but the role of many other ligands is not well understood and should not be underappreciated. Here, we provide a review of the current role of RAGE in melanoma and conclude that targeting RAGE in melanoma could be an approach to improve the outcomes of melanoma patients.
Keyphrases
- poor prognosis
- skin cancer
- end stage renal disease
- papillary thyroid
- long non coding rna
- chronic kidney disease
- basal cell carcinoma
- ejection fraction
- type diabetes
- insulin resistance
- metabolic syndrome
- peritoneal dialysis
- squamous cell
- prognostic factors
- young adults
- patient reported outcomes
- lymph node metastasis
- replacement therapy
- weight loss
- glycemic control